Heartflow develops non-invasive software that turns coronary CT scans into personalized 3D models of heart arteries and estimates fractional flow reserve (FFRCT). Its AI-assisted analysis helps clinicians assess coronary artery disease and decide on further testing or treatment without an invasive catheter procedure. Hospitals and cardiology practices use the technology as a decision-support tool in the diagnostic pathway.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 37.2 | — | -32.3 | — |
| Q2 2025 | 43.4 | — | -9.2 | — |
| Q3 2025 | 46.3 | — | -50.9 | — |
| Q4 2025 | 49.1 | — | -24.4 | — |
| Q1 2026 | 52.6 | 41.3% | -27.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Calumet, Inc. (CLMT), Ondas Inc. (ONDS), DLocal Limited (DLO), International Bancshares Corporation (IBOC), USA Rare Earth, Inc. (USAR), Celcuity Inc. (CELC)